Skip to main content

Peer Review reports

From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

Original Submission
15 Sep 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
17 Oct 2021 Reviewed Reviewer Report
24 Oct 2021 Reviewed Reviewer Report
10 Dec 2021 Author responded Author comments - Yoon Jun Kim
Resubmission - Version 3
10 Dec 2021 Submitted Manuscript version 3
20 Dec 2021 Author responded Author comments - Yoon Jun Kim
Resubmission - Version 4
20 Dec 2021 Submitted Manuscript version 4
5 Jan 2022 Author responded Author comments - Yoon Jun Kim
Resubmission - Version 5
5 Jan 2022 Submitted Manuscript version 5
3 Feb 2022 Reviewed Reviewer Report
3 Feb 2022 Reviewed Reviewer Report
14 Feb 2022 Author responded Author comments - Yoon Jun Kim
Resubmission - Version 6
14 Feb 2022 Submitted Manuscript version 6
5 Mar 2022 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
11 Mar 2022 Editorially accepted
25 Mar 2022 Article published 10.1186/s12876-022-02210-3

You can find further information about peer review here.

Back to article page